Published online Jan 7, 2018. doi: 10.3748/wjg.v24.i1.139
Peer-review started: October 9, 2017
First decision: October 25, 2017
Revised: November 13, 2017
Accepted: November 21, 2017
Article in press: November 21, 2017
Published online: January 7, 2018
Processing time: 91 Days and 18.1 Hours
To define probiotic monotherapy effect on Helicobacter pylori (H. pylori) status by performing a systematic review.
Methods of analysis and inclusion criteria were based on PRISMA recommendations. Relevant publications were identified by searching PubMed, MEDLINE, Science Direct, and EMBASE. The end-point was to estimate eradication rate and urea breath test delta value before and after probiotic monotherapy across all studies and, overall, with a pooled data analysis. Adverse events of probiotic therapy were evaluated. The data were expressed as proportions/percentages, and 95%CIs were calculated. For continuous variables, we evaluated the weighted mean difference. Odd ratios (ORs) were calculated according to the Peto method for the comparison of eradication rates between probiotics and placebo.
Eleven studies were selected. Probiotics eradicated H. pylori in 50 out of 403 cases. The mean weighted eradication rate was 14% (95%CI: 2%-25%, P = 0.02). Lactobacilli eradicated the bacterium in 30 out of 235 patients, with a mean weighted rate of 16% (95%CI: 1%-31%). Saccharomyces boulardii achieved eradication in 6 out of 63 patients, with a pooled eradication rate of 12% (95%CI: 0%-29%). Multistrain combinations were effective in 14 out of 105 patients, with a pooled eradication rate of 14% (95%CI: 0%-43%). In the comparison of probiotics vs placebo, we found an OR of 7.91 in favor of probiotics (95%CI: 2.97-21.05, P < 0.001). Probiotics induced a mean reduction in delta values higher than placebo (8.61% with a 95%CI: 5.88-11.34, vs 0.19% for placebo, P < 0.001). Finally, no significant difference in adverse events was found between probiotics and placebo (OR = 1, 95%CI: 0.06-18.08).
Probiotics alone show a minimal effect on H. pylori clearance, thus suggesting a likely direct role.
Core tip: Despite several lines of evidence in the literature having demonstrated a pivotal role of probiotics as adjunctive treatment for Helicobacter pylori (H. pylori) eradication, national and international guidelines do not have a uniform consensus about their clinical application. Many meta-analyses have confirmed that co-administration of probiotics may have a beneficial effect on the prevention of side effects and eradication rates. Herein, we found that probiotic monotherapy may eradicate H. pylori in 14% of cases. Lactobacilli, Saccharomyces boulardii and multistrain combinations eradicated the bacterium with a rate of 16%, 12% and 14%, respectively. Probiotics were significantly more effective than placebo (OR = 7.91).